SCHEMBL22327353

SCHEMBL22327353

Nc1ncnc2c1c(C#CCNC(=O)C(F)(F)F)cn2[C@H]1CC(O)[C@@H](CO)O1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.49
ADK P55263 2/20 0.43
DOT1L Q8TEK3 1/20 0.43
HIF1A Q16665 1/20 0.42
ADORA3 P0DMS8 1/20 0.41
ADORA2A P29274 1/20 0.41
PRMT5 O14744 3/20 0.40
METTL3 Q86U44 3/20 0.40
ATG7 O95352 3/20 0.40
DNMT1 P26358 2/20 0.39
FPR2 P25090 1/20 0.39
DNMT3B Q9UBC3 1/20 0.39
ADRB1 P08588 1/20 0.39
PNP P00491 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
HTT P42858 1/20 0.38
PDE4D Q08499 1/20 0.38
PDE3A Q14432 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12047324 1.00 CA2 (0.49) CA2ADKDOT1LHIF1AADORA3
SCHEMBL21912256 1.00 CA2 (0.49) CA2ADKDOT1LHIF1AADORA3
SCHEMBL21585106 1.00 CA2 (0.49) CA2ADKDOT1LHIF1AADORA3
SCHEMBL14104921 0.88 CA2 (0.47) CA2ADKDOT1LHIF1AADORA3
SCHEMBL10022897 0.86 CA2 (0.41) CA2ADKDOT1LPRMT5METTL3
SCHEMBL887484 0.86 CA2 (0.41) CA2ADKDOT1LPRMT5METTL3
SCHEMBL12047379 0.86 CA2 (0.41) CA2ADKDOT1LPRMT5METTL3
SCHEMBL12374617 0.85 ADK (0.62) CA2ADKDOT1LHIF1APRMT5
SCHEMBL26068620 0.84 CA2 (0.45) CA2ADKDOT1LPRMT5METTL3
SCHEMBL22327352 0.84 CA2 (0.47) CA2ADKPRMT5METTL3ATG7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257414-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2023-08-17 US disclosed
US-20230203083-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2023-06-29 US disclosed
US-20230028359-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2023-01-26 US disclosed
US-20220127299-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF LG ELECTRONICS INC. (KR) 2022-04-28 US disclosed
US-10822653-B1 Nucleotide cleavable linkers and uses thereof Singular Genomics Systems, Inc. (US) 2020-11-03 US disclosed
US-20200340051-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2020-10-29 US disclosed
US-10738072-B1 Nucleotide analogues Singular Genomics Systems, Inc. (US) 2020-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200340051-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF NUDT21, CPSF7, DCLRE1A CA2 3956/4885ADK 660/4885DOT1L 2138/4885
US-20220127299-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF NUDT21, CPSF7, DCLRE1A CA2 3956/4885ADK 660/4885DOT1L 2138/4885
US-20230257414-A1 NUCLEOTIDE ANALOGUES ITPA, POLB, NUDT1 CA2 4091/4885ADK 366/4885DOT1L 2575/4885
US-10822653-B1 Nucleotide cleavable linkers and uses thereof NUDT21, CPSF7, DCLRE1A CA2 3956/4885ADK 660/4885DOT1L 2138/4885
US-20230028359-A1 NUCLEOTIDE ANALOGUES ITPA, POLB, NUDT1 CA2 4091/4885ADK 366/4885DOT1L 2575/4885
US-10738072-B1 Nucleotide analogues NUDT1, POLN, TYMP CA2 4567/4885ADK 195/4885DOT1L 2328/4885
US-20230203083-A1 NUCLEOTIDE ANALOGUES ITPA, POLB, NUDT1 CA2 4091/4885ADK 366/4885DOT1L 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.